Fundraising Fox
Cambrian Bio
New York, US · Founded 2019 · Delaware corporation · 30 employees on LinkedIn · 11 known investors
Find your way into Cambrian Bio
Sign up to see every warm intro you have to Cambrian Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cambrian Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cambrian Bio is a clinical-stage drug development company creating precision therapeutics that target metabolic pathways which decline with age, such as AMPK and mTOR. Its lead asset, ATX-304, is an AMPK Network Activator being developed for obesity and prediabetes.
Founders & leadership
Cambrian Bio was founded in 2019 by James Peyer.
JP
James PeyerCEO, Founder, Board DirectorJames Peyer is founder and CEO of Cambrian Bio, a clinical-stage drug development company creating therapeutics targeting metabolic pathways such as AMPK and mTOR. Previously, he founded and served as CEO of Apollo Ventures, a company builder focused on longevity therapeutics, and completed a PhD in blood stem cell biology at UT Southwestern as an NSF Fellow.
RT
Ruth Thieroff-EkerdtEVP Clinical DevelopmentRuth Thieroff-Ekerdt is Chief Medical Officer at Cambrian Bio, a clinical-stage biotech company developing precision therapeutics targeting age-related metabolic decline. She brings over 30 years of pharmaceutical R&D experience spanning drug discovery, clinical development, and regulatory affairs across large and small companies, with a track record of EMA and FDA interactions leading to approvals in rare diseases, gastrointestinal, autoimmune, dermatology, and women's health.
BD
Bill DeVaulChief Legal OfficerHe has held executive and legal roles at multiple public biopharmaceutical companies and has experience in corporate financings, M&A, intellectual property strategy, and corporate governance.
Board
CA
Christian AngermayerChairman, Co-Founder, Board DirectorFounder and Chairman of the Board at atai Life Sciences
MS
CA
Christian AngermeyerBoard director
PF
Paul FarrBoard director
JH
MG
Martin GunhagaBoard director
LV
Lorin Van NulandBoard director
Investors · 11
Catalio Capital Management, LPlisted by Catalio Capital Management, LPNew York
How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us
Future Ventureslisted by Future VenturesLos Altos · $1M – $10M
How we know: Future Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Khosla Ventureslisted by Khosla VenturesMenlo Park · $100K – $20M
How we know: Khosla Ventures's portfolio page · Not right? Tell us
Korify Capitallisted by Korify Capital
How we know: Korify Capital's portfolio page · Not right? Tell us
Strawberry Creek Ventureslisted by Strawberry Creek VenturesManchester
How we know: Strawberry Creek Ventures's portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$272.2M disclosed across 5 rounds · 2019–2026
▶$123.8MraisedJul 2026 · 80 investors · BiotechnologyRule 506(c)
▶$123.8MraisedJul 2026 · 80 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- James PeyerExecutive Officer, Director
- Juliette HanExecutive Officer, Director
- Mark NuttallExecutive Officer
- Ruth Thieroff-EkerdtExecutive Officer
- William DeVaulExecutive Officer
- Christian AngermeyerDirector
- Maryanna SaenkoDirector
- Brenton L. SaundersDirector
- Paul FarrDirector
- Martin GunhagaDirector
- Lorin Van NulandDirector
- Offering amount
- $129.8M
- Amount sold
- $123.8M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$23MraisedJan 2025 · 30 investors · PharmaceuticalsRule 506(b)
▶$23MraisedJan 2025 · 30 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christian AngermayerDirector
- Maryanna SaenkoDirector
- Paul FarrDirector
- James G. PeyerExecutive Officer, Director
- Brenton SaundersDirector
- Offering amount
- $37.6M
- Amount sold
- $23M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$92.2MraisedDec 2021 · 56 investors · PharmaceuticalsRule 506(b)
▶$92.2MraisedDec 2021 · 56 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christian AngermayerDirector
- Maryanna SaenkoDirector
- James G. PeyerExecutive Officer, Director, Promoter
- Offering amount
- $100.8M
- Amount sold
- $92.2M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$28.4MraisedMay 2021 · 30 investors · PharmaceuticalsRule 506(b)
▶$28.4MraisedMay 2021 · 30 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James G. PeyerExecutive Officer, Director, Promoter
- Christian AngermeyerDirector
- Maryanna SaenkoDirector
- Offering amount
- $28.4M
- Amount sold
- $28.4M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$4.8MraisedJan 2020 · 5 investors · PharmaceuticalsRule 506(b)
▶$4.8MraisedJan 2020 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christian AngermeyerDirector
- James G. PeyerExecutive Officer, Director, Promoter
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
The Cambrian Bio mafia →8 people who came through Cambrian Bio went on to found or lead other companies.
Christian AngermayerChairman, Co-Founder, Board DirectorFounded Apeiron Investments +1James PeyerCEO, Founder, Board DirectorFounded Rapalogix Health +1Janett LirianoFirst employee & Chief of StaffFounded Inaru +1Maryanna SaenkoDirectorFounded Future VenturesViktoriya TigipkoSeed InvestorFounded TA VenturesJuliette HanChief Financial Officer & Chief Operating OfficerFounded Two SigmaSebastian BrunemeierCIO & Co-FounderFounded Cyclone TherapeuticsShalini GuptaProduct ConsultantFounded Asima Health
Related companies · 2
BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Cambrian Bio.
Frequently asked questions
- What does Cambrian Bio do?
- Cambrian Bio is a clinical-stage drug development company creating precision therapeutics that target metabolic pathways which decline with age, such as AMPK and mTOR. Its lead asset, ATX-304, is an AMPK Network Activator being developed for obesity and prediabetes.
- Who founded Cambrian Bio?
- Cambrian Bio was founded by James Peyer in 2019.
- Who are Cambrian Bio's investors?
- Cambrian Bio's investors include Alumni Ventures, Catalio Capital Management, LP, FJ Labs, Future Ventures, Khosla Ventures, Korify Capital, Sprint Vc, Strawberry Creek Ventures and 3 more.
- How much funding has Cambrian Bio raised?
- Cambrian Bio has disclosed $272.2M raised across 5 rounds.
- Where is Cambrian Bio headquartered?
- Cambrian Bio is headquartered in New York, US.